State Board of Administration of Florida Retirement System reduced its stake in Hologic (NASDAQ:HOLX) by 0.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 410,779 shares of the medical equipment provider’s stock after selling 3,051 shares during the period. State Board of Administration of Florida Retirement System owned approximately 0.15% of Hologic worth $15,347,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Parnassus Investments CA grew its stake in shares of Hologic by 88.6% in the 4th quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock worth $608,797,000 after buying an additional 6,689,454 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Hologic by 28.1% in the 4th quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock worth $120,910,000 after buying an additional 620,761 shares in the last quarter. Guggenheim Capital LLC grew its stake in shares of Hologic by 46.0% in the 4th quarter. Guggenheim Capital LLC now owns 1,662,053 shares of the medical equipment provider’s stock worth $71,053,000 after buying an additional 523,654 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Hologic in the 4th quarter worth $18,383,000. Finally, Victory Capital Management Inc. grew its stake in shares of Hologic by 5.8% in the 4th quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock worth $265,008,000 after buying an additional 342,239 shares in the last quarter. Institutional investors own 98.47% of the company’s stock.
HOLX has been the subject of a number of recent research reports. Canaccord Genuity reissued a “buy” rating and issued a $48.00 price objective on shares of Hologic in a research note on Friday, February 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a research note on Friday, February 9th. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, February 13th. Goldman Sachs set a $43.00 price target on shares of Hologic and gave the stock a “buy” rating in a research note on Tuesday, April 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $44.00 price target on shares of Hologic in a research note on Sunday, May 6th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $44.87.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.53. The company had revenue of $789.30 million during the quarter, compared to analysts’ expectations of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.50 EPS. research analysts expect that Hologic will post 2.24 earnings per share for the current fiscal year.
In other Hologic news, SVP Allison P. Bebo sold 7,000 shares of the business’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $38.75, for a total value of $271,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles J. Dockendorff acquired 13,000 shares of the stock in a transaction on Thursday, March 15th. The stock was bought at an average cost of $38.80 per share, with a total value of $504,400.00. The disclosure for this purchase can be found here. 0.79% of the stock is owned by insiders.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.